<DOC>
<ID> XIE19961215.0069 </ID>
<DATE_TIME> 1996-12-15 </DATE_TIME>
<BODY>
<HEADLINE> Two New Hepatitis Drugs Being Tested: Expert </HEADLINE>
<TEXT>
<P>
NEW DELHI, December 15 (Xinhua) -- Two new drugs that e Press Trust of
India while attending a symposium on transfusion associated
hepatitis here.
</P>
<P>
Interferon-based therapy, however, works only in one-third of
the cases, while about 70 percent of the patients do not benefit
from it.
</P>
<P>
The two drugs -- lamivudine and famciclovir -- can be given
orally and are well-tolerated, Thomas said.
</P>
<P>
They are expected to have fewer side-effects compared to
interferons that cause fever and lethargy.
</P>
<P>
The drugs have completed Phase I and Phase II trials for safety
and efficacy, and are currently undergoing Phase III multi-centric
trials in the United States, Europe and Southeast Asia.
</P>
<P>
The trials, being conducted by a team of 20 investigators,
commenced a year ago and their results are expected to be out in
1997.
</P>
<P>
Experts are also working on an improved modified vaccine for
hepatitis-B, Thomas said.  
</P>
</TEXT>
</BODY>
</DOC>